Compare iShares MSCI Indonesia ETF (EIDO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.18, while Sana Biotechnology Inc trades at $3.16 (market cap $987.94M). Which is the better fit depends on your goals.
| EIDO | SANA | |
|---|---|---|
52-Week High | $19.22 | $5.92 |
52-Week Low | $10.80 | $2.68 |
Market Cap | — | $987.94M |
Sector | — | Health |
Enterprise Value | — | $962.13M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.205, up 1.12% on the day, while technical indicators signal a bearish trend with moving averages and an overbought short-term RSI. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal plan and central bank rate hikes to support the currency. However, key financial ratios for the underlying fund holdings are unavailable in the provided data.
The outlook is mixed, balancing Indonesia's long-term GDP growth potential from government programs against near-term risks from currency volatility and geopolitical pressures. The ETF's dividend yield remains a draw, but a reported 27% dividend cut in 2025 signals underlying economic challenges for income-focused investors.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
